UH Seidman Cancer Center Researcher Awarded New Gastrointestinal Cancer Grant from NCCN in Collaboration with Taiho Oncology, Inc.

CLEVELAND – Gastrointestinal cancers represent a significant global health burden, with colorectal and gastric cancers among the most common malignancies worldwide. Despite advancements in treatment, many patients face limited options, particularly in advanced stages of the disease. A group of three grants awarded to several researchers, including Madison Conces, MD, UH Seidman Cancer Center/Case Comprehensive Cancer Center hopes to move that research forward.

The National Comprehensive Cancer Network^® (NCCN^®) Oncology Research Program (ORP) announced the new funding aimed at advancing clinical research in gastrointestinal cancers. The grants have been awarded to innovative investigator-initiated research to explore the potential of trifluridine/tipiracil (FTD/TPI) and/or futibatinib in treating gastrointestinal cancers.

The goal of this program is to enhance understanding of the therapeutic applications of FTD/TPI and futibatinib to potentially address unmet needs.

“I am honored that my clinical trial proposal was selected for funding. I hope this study will help improve treatment for patients with advanced or metastatic biliary tract cancer and look forward to how this study will contribute to other future investigations as well,” said Dr. Conces.

The initiative is made possible through a research grant provided by Taiho Oncology, Inc.

“Innovative research is essential for driving progress in cancer care,” said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. “We are proud to support these investigators as they explore new ways to potentially improve outcomes for patients with gastrointestinal cancers. These grants will enable the exploration of novel strategies and combinations that could lead to more effective options in the future.”